AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 72 filers reported holding AMYLYX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,795,995 | -25.5% | 425,778 | -12.3% | 0.00% | 0.0% |
| Q2 2023 | $10,470,466 | -23.1% | 485,418 | +4.6% | 0.00% | -33.3% |
| Q1 2023 | $13,610,240 | -6.8% | 463,880 | +17.4% | 0.00% | 0.0% |
| Q4 2022 | $14,600,386 | +81.5% | 395,139 | +38.3% | 0.00% | +50.0% |
| Q3 2022 | $8,045,000 | +341.8% | 285,808 | +202.3% | 0.00% | – |
| Q2 2022 | $1,821,000 | +72.4% | 94,541 | +15.1% | 0.00% | – |
| Q1 2022 | $1,056,000 | – | 82,170 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,948,214 | $37,523,000 | 4.40% |
| Boxer Capital, LLC | 2,200,000 | $42,372,000 | 2.68% |
| Perceptive Advisors | 3,540,408 | $68,188,000 | 2.14% |
| Altium Capital Management LP | 200,000 | $3,852,000 | 1.54% |
| Alpha Wave Global, LP | 700,635 | $13,494,000 | 1.39% |
| Ikarian Capital, LLC | 350,800 | $6,757,000 | 1.23% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 768,603 | $14,804,000 | 1.07% |
| 683 Capital Management, LLC | 677,714 | $12,958,000 | 0.92% |
| Ikarian Capital, LLC | 246,554 | $4,750,000 | 0.87% |
| Tri Locum Partners LP | 80,459 | $1,550,000 | 0.64% |